{"entity":{"id":"nct06154291","kind":"trial","name":"FIH XON7 in Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of XON7 in advanced solid tumours, run by Xenothera SAS, now recruiting.","summary":"FIH XON7 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06154291 by Xenothera SAS, with 255 participants planned, started 2023-11-14 and due to reach its primary completion in 2026-12. Interventions recorded: XON7.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06154291","url":"https://clinicaltrials.gov/study/NCT06154291"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06154291","phase":"1/2","setting":"Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-tumors Efficacy of the Glyco-humanized Polyclonal Antibody XON7 in Patients With Advanced or Metastatic Solid Tumors","sponsor":"Xenothera SAS","enrolled":255,"outcomes":[]},"route":"/trials/nct06154291/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}